PubMed · 9565053
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
N M Bressler. 1998. Evaluating new retinal imaging techniques.. https://doi.org/10.1001/archopht.116.4.521
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
OBJECTIVE: The decision tree analysis is based on a study of v. Doern comparing the medical costs of a diagnosis by means of a traditional method (ONAST) to a new and quicker method (RAST). The conclusion is that, the traditional method proofs to be more expensive regarding different types of costs. A goal of this analysis was to prove the results of this US study for an application in the German health care system. METHODS: A cost efficacy analysis by means of a decision tree was carried out measuring the costs using the surviving of patients as a parameter. As in the RAST group 24 out of 273 and in the ONAST group 46 in 300 persons died, the efficacy rates amount to 0.912 and 0.847, respectively. Finally, sensitivity analyses were performed. RESULTS: Results of total (direct and indirect) costs per surviving patient showed an advantage of the RAST procedure amounting to DM 3,653 (28.3%) compared to the ONAST procedure. From the perspective of a German sickness fund, the RAST procedure leads to a saving potential of about DM 2,671 (13.0%) in comparison to the ONAST procedure. As a result, a minimum of 10 patients a year are required to save costs from the perspective of the hospital. If costs for drugs in the RAST procedure amount to DM 8,764.93, equality of total costs is obtained. This case is rather unlikely. CONCLUSION: From both perspectives of the payer as well as that of the hospital it can be concluded that the rapid method is more cost-effective than the overnight method.
Introduction and application of new technologies in the Dutch health care system will be less straightforward in the future than they were in the past. The pressure to contain health care expenditure has increased, also because of European agreements about adequate financing of collective spending. This will make initiators and producers of new technologies more critical towards technologies currently in development and urge them to specifically introduce technologies with a relatively favourable cost effectiveness profile. Whether new technologies will be used to a large extent will increasingly depend on the parties in health care at the regional and practice levels, who will assume a more important role in resource allocation in health care. On the other hand, they will be made more accountable for their decisions and will have to demonstrate their contribution to efficiency in health care.
Explore the source record for details and available documents.